HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic
Latest funding led by Mirae Asset Financial Group and joined by B Capital Group, Sherpa,…